Why Exact Sciences Dropped 13.2% in February
Shares of cancer diagnostics company Exact Sciences (NASDAQ: EXAS) dropped 13.3% in January, according to the latest report from S&P Global Market Intelligence. That move erased 2019 gains and reduced the stock price to new 52-week lows.
The company produces Cologuard, the non-invasive screen for colon cancer, as well as other cancer diagnostic and monitoring products.
Such a precipitous drop in a stock recommended as a buy by 15 out of 15 Wall Street analysts is pretty attention-getting and demands analysis. Was it caused by a fundamental issue or an unfortunate confluence of events?
Source Fool.com
